In the Winter 2022 edition of “European Biotechnology“ magazine, from December, the cover story “Biotech Financing – Crisis? What Crisis?” focuses on 2022 as “the most difficult year for mergers and acquisitions in biotech since … Read more
On March 8, 2022, the Süddeutsche Zeitung reports online about the current situation for medium-sized companies – supply bottlenecks and rising energy costs are showing their effects on medium-sized companies and also on consumers. Arno … Read more
On Thursday, June 10, the German newspaper “Handelsblatt” reported online and in its print version on the planned IPO of ATAI Life Sciences, a German company specializing in psychedelic drugs. Previously labeled as narcotic drugs, … Read more
FCF Life Sciences in the Börse Online magazine | 19. April 2021 The Life Sciences team at FCF Fox Corporate Finance has recently published an analysis on Special Purpose Acquisition Companies (SPACs) with a focus … Read more
Der Boom um Special Purpose Acquisition Companies, auch SPACs genannt, setzt sich 2021 ungebremst fort. Lag die Zahl der SPAC-Börsengänge im gesamten Jahr 2020 noch bei 306 SPAC-IPOs, liegt sie in den ersten drei Monaten … Read more
Der deutsche Markt erlebt hier seinen schonungslosen Moment der Wahrheit Dass die Corona-Krise besondere Entwicklungen mit sich bringt, ist in vielen Bereichen zu spüren. Die Auswirkungen der Ausbreitung des Virus sind in dieser Form noch … Read more
German life science companies must raise more money abroad The fact that Germany’s life sciences industry is doing very well in European comparison is due to a few big deals. The latest venture capital research … Read more
By Dr. Mathias Schott and Sebastian Sommer To start off with the good news, Bavaria has proven its position within the German Biotech scene last year. The Free State accounted for an astonishing 40 percent of the German … Read more
Interview mit Arno Fuchs, CEO, FCF Fox Corporate Finance Die Plattform Life Sciences sprach mit Arno Fuchs über Deutschlands Life-Sciences-Branche im internationalen Vergleich, bedenkliche Entwicklungen und kostspielige (verpasste) Weichenstellungen. Plattform Life Sciences: Herr Fuchs, nimmt Deutschland … Read more
